Skip to content
Screener

Opko Health OPK Pre-Tax Income

Pre-Tax Income at other companies

Quest Diagnostics logo
Quest DiagnosticsDGX
$412M+7.3%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$11.66M+1.3%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$91M+20.2%
PTH
Pelthos TherapeuticsPTHS
-$10.24M-420%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$74.03M-34.0%
ALN
Alnylam PharmaceuticalsALNY
$177.81M+603%

Other financials

Income statement

See full
Revenue$163.6M+4.3%
Gross profit$80.0M+62.0%
Operating income-$7.0M+88.4%
Net income-$8.4M+94.3%
EPS (diluted)-$0.01+94.7%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$49.9M-7.5%
Total equity$1.2B-8.7%
Total assets$1.8B-7.3%

Cash flow

See full
Operating cash flow-$43.5M+47.9%
CapEx$3.0M-8.5%
Free cash flow-$46.5M+46.4%

Valuation

See full
Market cap$985.15M-2.3%
P/S1.7×+0.2×

Profitability

See full
Gross margin40.8%+8.1pp
Operating margin-8.2%-3.5pp
Net margin-12.4%-4.3pp
FCF margin-22.8%-6.7pp

Returns & leverage

See full
Return on equity-5.9%-2.1pp
Debt / equity0.0×
Current ratio3.3×-0.1×

Where this comes from

Reported directly by Opko Health in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments.

The source filing: Opko Health’s 10-Q, filed July 27, 2026.

Filed
Jul 27, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-318090
Line itemFor the three months ended June 30, 2026For the three months ended June 30, 2025For the six months ended June 30, 2026For the six months ended June 30, 2025
Fair value changes of derivative instruments, net(65)16(363)(257)
Other income (expense), net1,797(35,515)86(30,663)
Other expense, net(6,427)(102,539)(16,368)(108,746)
Loss before income taxes and investment losses(13,399)(162,520)(74,355)(235,894)
Income tax benefit4,98314,07911,09319,849
Net loss before investment losses(8,416)(148,441)(63,262)(216,045)
Loss from investments in investees(2)(9)
Net loss$(8,416)$(148,441)$(63,264)$(216,054)

Item 1. Financial Statements

FAQ

What is Opko Health's pre-tax income?
Opko Health (OPK) reported pre-tax income of -$13.4M in Q2 2026.
How has Opko Health's pre-tax income changed year-over-year?
Opko Health's pre-tax income increased by 91.8% year-over-year, from -$162.52M to -$13.4M.
What is the long-term trend for Opko Health's pre-tax income?
Over 2 years (2021 to 2025), Opko Health's pre-tax income has grown at a 314.8% compound annual growth rate (CAGR), from -$14.03M to -$241.36M.
What does pre-tax income mean?
Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Ask your AI about Opko Health's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude